| Project/Area Number |
25462254
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
Arakawa Yoshiki 京都大学, 医学(系)研究科(研究院), 助教 (20378649)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
Dean Thumkeo 京都大学, 医学研究科, 助教 (40372594)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Matsuda Michiyuki 京都大学, 医学研究科, 教授 (10199812)
|
|---|
| Research Collaborator |
Murata Daiki
Fujimoto Ko-ichi
Yokogawa Ryuta
Terada Yukinori
Fukui Nobuyuki
Liu Bin
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 悪性脳腫瘍 / ワクシニアウイルス / 生体イメージング / 腫瘍免疫 / 免疫誘導 / ウイルス治療 / 悪性グリオーマ |
|---|
| Outline of Final Research Achievements |
The aim of the project is to analyze oncolytic bioresponse induced by vaccinia virus, and to develop the new oncolytic therapy. Our previous results indicate that the antitumor immunity activated by vaccinia virus is effective for malignant brain tumors. In brain tumor models, the induction of antitumor immune competent cells was identified by immunohistochemical staining and flow cytometry, although it was not sufficient for long-term tumor control. As Flt3L is known to be a strong stimulator of antitumor immune system, Flt3L-expressing vaccinia virus has been developed. The in vivo analyzing system of antitumor immunity has been prepared to evaluate efficacy of Flt3L-expressing vaccinia virus. The status of antitumor immunity in medulloblastoma was analyzed. We confirmed that high PD-L1 expression and low CD8+ lymphocyte infiltration was associated with worse survival in patients with medulloblastoma.
|
